AR and metastatic prostate carcinoma: The overwhelmingly oncogenic role of androgen/AR-pathway in supporting the growth and survival of metastatic prostate cancer dictates that androgen/AR-targeted therapy is the best treatment option for patients with the metastatic disease1,2.